IP Library › Granted Patent US 12,371,499
Granted Patent B2
US 12,371,499 · App. 17/743,578 · Granted Jul 29, 2025

Method of treating cancer using anti-AV8 antibodies

Inventors: Kyle Steven Niessen (Edina, MN); Dharmaraj Samuel (Dublin, CA); Charles Ray Holst (San Jose, CA); Matthew Ross Drever (Concord, CA); Dean Sheppard (Oakland, CA); Rosemary J. Akurst (Tiburon, CA); Amha Atakilit (Oakland, CA); Dominique Meyer (El Cerrito, CA); Isaac J. Rondon (San Francisco, CA); Joseph Dal Porto (Los Gatos, CA)
Assignees: The Regents of the University of California; Pfizer, Inc.
C07K16/2839C07K16/2818C07K16/2878A61K39/3955A61K2039/505A61K2039/507C07K2317/24C07K2317/33C07K2317/55C07K2317/565C07K2317/71
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,499
App. No.
17/743,578
Granted
Jul 29, 2025
Kind
B2
Abstract

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to αvβ8 integrin. The invention includes uses, and associated methods of using the antibodies.

Claims (57)

1. A method of treating a cancer in a subject, comprising administering to the subject, a therapeutically effective amount of an antibody or antigen-binding fragment thereof, that specifically binds αvβ8 integrin, wherein the antibody or antigen-binding fragment thereof is at least one antibody or antigen-binding fragment thereof selected from the group consisting of:

(a) an antibody or antigen-binding fragment thereof, comprising a light chain complementarity determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 12; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13; a heavy chain CDR1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 8; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 9; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) an antibody or antigen-binding fragment thereof, comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 18; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H1 comprising the amino acid sequence of SEQ ID NO:14; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 15; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16;

(c) an antibody or antigen-binding fragment thereof, comprising a variable light (VL) region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC and having Accession Number PTA-124918, and a variable heavy (VH) region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC having Accession Number PTA-124917;

(d) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 7, and a VH region comprising the amino acid sequence of SEQ ID NO: 6;

(e) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 47 and a VH region comprising the amino acid sequence of SEQ ID NO: 39, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 92 and a VH region comprising the amino acid sequence of SEQ ID NO: 39;

(f) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 67 and a VH region comprising the amino acid sequence of SEQ ID NO: 6, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 69 and a VH region comprising the amino acid sequence of SEQ ID NO: 6, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 7 and a VH region comprising the amino acid sequence of SEQ ID NO: 93, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 67 and a VH region comprising the amino acid sequence of SEQ ID NO: 93, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 69 and a VH region comprising the amino acid sequence of SEQ ID NO: 93;

(g) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 47 and a VH region comprising the amino acid sequence of SEQ ID NO: 90, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 47 and a VH region comprising the amino acid sequence of SEQ ID NO: 6, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 92 and a VH region comprising the amino acid sequence of SEQ ID NO: 90;

(h) an antibody or antigen-binding fragment thereof, comprising a light chain (LC) region comprising the amino acid sequence of SEQ ID NO: 5, and a heavy chain (HC) region comprising the amino acid sequence of SEQ ID NO: 2;

(i) an antibody or antigen-binding fragment thereof, comprising a LC region comprising the amino acid sequence of SEQ ID NO: 5, and a HC region comprising the amino acid sequence of SEQ ID NO: 3;

(j) an antibody or antigen-binding fragment thereof, comprising a LC region comprising the amino acid sequence of SEQ ID NO: 123, and a HC region comprising the amino acid sequence of SEQ ID NO: 124 or 182;

(k) an antibody or antigen-binding fragment thereof, comprising a VL region encoded by the nucleic acid sequence of SEQ ID NO: 186, and a VH region encoded by the nucleic acid sequence of SEQ ID NO: 190; and

(l) an antibody or antigen-binding fragment thereof, comprising a LC region encoded by the nucleic acid sequence of SEQ ID NO: 185, and a HC region encoded by the nucleic acid sequence of SEQ ID NO: 189 or 191.

2. The method of claim 1 , further administering to the subject a cytotoxic agent, a cytostatic agent, a chemotherapeutic agent, a hormone treatment, a vaccine, an immunotherapy, surgery, radiation, thermotherapy, or a combination thereof.

3. The method of claim 2 , wherein the further administering is simultaneous, sequential or separate from the administration of the therapeutically effective amount of the antibody or antigen-binding fragment thereof.

4. The method of claim 2 , wherein the immunotherapy comprises a inhibitor of an immune checkpoint molecule selected from the group consisting of an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, a soluble CTLA-4 fusion protein and a combination thereof.

5. The method of claim 1 , wherein the cancer is selected from the group consisting of squamous cell carcinoma of the head and neck, renal cell carcinoma with clear cell or papillary cell type, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung squamous cell cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, uterine cancer, melanoma, urothelial carcinoma and combinations thereof.

6. The method of claim 1 , further comprising administering to the subject an inhibitor of PD1, PD-L1, or PD-L2.

7. The method of claim 6 , wherein the cancer is a squamous cell carcinoma.

8. The method of claim 6 , wherein the cancer is breast or colon cancer.

9. The method of claim 6 , wherein the inhibitor is selected from the group consisting of an anti-PD1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody.

10. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 12; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 9; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 10.

11. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 18; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 15; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16.

12. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a VL region comprising the amino acid sequence of SEQ ID NO: 7, and a VH region comprising the amino acid sequence of SEQ ID NO: 6.

13. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a VL region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC and having Accession Number PTA-124918, and a VH region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC having Accession Number PTA-124917.

14. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a LC region comprising the amino acid sequence of SEQ ID NO: 5, and a HC region comprising the amino acid sequence of SEQ ID NO: 2 or 3.

15. The method of claim 1 , where the antibody or antigen-binding fragment thereof comprises a VL region comprising a VL region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 47 and 92, and a VH region comprising the amino acid of SEQ ID NO: 39.

16. The method of claim 1 , where the antibody or antigen-binding fragment thereof comprises a VL region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 7, 67, or 69, and a VH region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 6 and 93.

17. The method of claim 1 , where the antibody or antigen-binding fragment thereof comprises a VL region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 47 and 92, and a VH region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: and 90.

18. A method of improving survival rate of a subject having a cancer, decreasing the appearance of cancer lesions, decreasing the extent of tissue damage from the cancer, decreasing the duration of the cancer, and/or reducing the number, extent, or duration of symptoms related to the cancer, comprising administering to the subject, a therapeutically effective amount of an antibody or antigen-binding fragment thereof, that specifically binds αvβ8 integrin, wherein the antibody or antigen-binding fragment thereof is at least one antibody or antigen-binding fragment thereof selected from the group consisting of:

(a) an antibody or antigen-binding fragment thereof, comprising a light chain complementarity determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 12; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13; a heavy chain CDR1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 8; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 9; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) an antibody or antigen-binding fragment thereof, comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 18; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H1 comprising the amino acid sequence of SEQ ID NO:14; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 15; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16;

(c) an antibody or antigen-binding fragment thereof, comprising a variable light (VL) region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC and having Accession Number PTA-124918, and a variable heavy (VH) region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC having Accession Number PTA-124917;

(d) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 7, and a VH region comprising the amino acid sequence of SEQ ID NO: 6;

(e) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 47 and a VH region comprising the amino acid sequence of SEQ ID NO: 39, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 92 and a VH region comprising the amino acid sequence of SEQ ID NO: 39;

(f) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 67 and a VH region comprising the amino acid sequence of SEQ ID NO: 6, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 69 and a VH region comprising the amino acid sequence of SEQ ID NO: 6, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 7 and a VH region comprising the amino acid sequence of SEQ ID NO: 93, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 67 and a VH region comprising the amino acid sequence of SEQ ID NO: 93, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 69 and a VH region comprising the amino acid sequence of SEQ ID NO: 93;

(g) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 47 and a VH region comprising the amino acid sequence of SEQ ID NO: 90, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 47 and a VH region comprising the amino acid sequence of SEQ ID NO: 6, or an antibody of antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 92 and a VH region comprising the amino acid sequence of 90;

(h) an antibody or antigen-binding fragment thereof, comprising a light chain (LC) region comprising the amino acid sequence of SEQ ID NO: 5, and a heavy chain (HC) region comprising the amino acid sequence of SEQ ID NO: 2;

(i) an antibody or antigen-binding fragment thereof, comprising a LC region comprising the amino acid sequence of SEQ ID NO: 5, and a HC region comprising the amino acid sequence of SEQ ID NO: 3;

(j) an antibody or antigen-binding fragment thereof, comprising a LC region comprising the amino acid sequence of SEQ ID NO: 123, and a HC region comprising the amino acid sequence of SEQ ID NO: 124 or 182;

(k) an antibody or antigen-binding fragment thereof, comprising a VL region encoded by the nucleic acid sequence of SEQ ID NO: 186, and a VH region encoded by the nucleic acid sequence of SEQ ID NO: 190; and

(l) an antibody or antigen-binding fragment thereof, comprising a LC region encoded by the nucleic acid sequence of SEQ ID NO: 185, and a HC region encoded by the nucleic acid sequence of SEQ ID NO: 189 or 191.

19. A method of inhibiting αvβ8 integrin binding, comprising administering to a subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof, that specifically binds αvβ8 integrin, wherein the antibody or antigen-binding fragment thereof is at least one antibody or antigen-binding fragment thereof selected from the group consisting of:

(a) an antibody or antigen-binding fragment thereof, comprising a light chain complementarity determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 12; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13; a heavy chain CDR1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 8; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 9; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) an antibody or antigen-binding fragment thereof, comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 18; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H1 comprising the amino acid sequence of SEQ ID NO:14; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 15; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16;

(c) an antibody or antigen-binding fragment thereof, comprising a variable light (VL) region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC and having Accession Number PTA-124918, and a variable heavy (VH) region comprising the amino acid sequence encoded by the insert of the plasmid deposited with the ATCC having Accession Number PTA-124917;

(d) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence of SEQ ID NO: 7, and a VH region comprising the amino acid sequence of SEQ ID NO: 6;

(e) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 62-66, and a VH region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 34-38;

(f) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 47 and 92, and a VH region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 39 and 88-91;

(g) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 7 and 67-69, and a VH region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 6 and 93;

(h) an antibody or antigen-binding fragment thereof, comprising a VL region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 7, 47-69 and 92, and a VH region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 6, 34-46, 88-91 and 93;

(i) an antibody or antigen-binding fragment thereof, comprising a light chain (LC) region comprising the amino acid sequence of SEQ ID NO: 5, and a heavy chain (HC) region comprising the amino acid sequence of SEQ ID NO: 2;

(j) an antibody or antigen-binding fragment thereof, comprising a LC region comprising the amino acid sequence of SEQ ID NO: 5, and a HC region comprising the amino acid sequence of SEQ ID NO: 3;

(k) an antibody or antigen-binding fragment thereof, comprising a LC region comprising the amino acid sequence of SEQ ID NO: 123, and a HC region comprising the amino acid sequence of SEQ ID NO: 124 or 182;

(l) an antibody or antigen-binding fragment thereof, comprising a VL region encoded by the nucleic acid sequence of SEQ ID NO: 186, and a VH region encoded by the nucleic acid sequence of SEQ ID NO: 190; and

(m) an antibody or antigen-binding fragment thereof, comprising a LC region encoded by the nucleic acid sequence of SEQ ID NO: 185, and a HC region encoded by the nucleic acid sequence of SEQ ID NO: 189 or 191.

20. The method of claim 19 , where the subject has a cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2025
From: SHEPPARD, DEAN; AKHURST, ROSEMARY J.; ATAKILIT, AMHA; MEYER, DOMINIQUE; NIESSEN, KYLE STEVEN; SAMUEL, DHARMARAJ; HOLST, CHARLES RAY; DREVER, MATTHEW ROSS; RONDON, ISAAC J.; DAL PORTO, JOSEPH
To: PFIZER INC.; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 071483/0206 →
Continuity (4)
Division 16561530 · Sep 5, 2019
Provisional Application 62890945 · Aug 23, 2019
Provisional Application 62728688 · Sep 7, 2018
Related Publication 20220289850A1 · Sep 15, 2022
References Cited (102)
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 7501121B2 · Tchistiakova et al. · 2009 [cited by applicant]
US 9217039B2 · Pedersen et al. · 2015 [cited by applicant]
US 9290572B2 · Nishimura et al. · 2016 [cited by applicant]
US 9969804B2 · Sheppard et al. · 2018 [cited by applicant]
US 10167334B2 · Mirza et al. · 2019 [cited by applicant]
US 10597455B2 · Sheppard et al. · 2020 [cited by applicant]
US 11359024B2 · Niessen et al. · 2022 [cited by applicant]
US 20090155256A1 · Black et al. · 2009 [cited by applicant]
US 20160046717A1 · Sheppard et al. · 2016 [cited by applicant]
US 20190144547A1 · Celik et al. · 2019 [cited by applicant]
US 20200079855A1 · Niessen et al. · 2020 [cited by applicant]
US 20200247891A1 · Sheppard et al. · 2020 [cited by applicant]
CN 103857696A · 2014 [cited by applicant]
CO 2022011661A2 · 2022 [cited by applicant]
EP 2744823A2 · 2014 [cited by applicant]
JP 2015501285A · 2015 [cited by applicant]
RU 2565539C2 · 2015 [cited by applicant]
RU 2614252C2 · 2017 [cited by applicant]
WO WO2008141276A1 · 2008 [cited by applicant]
WO WO2011020529A2 · 2011 [cited by applicant]
WO WO2011103490A2 · 2011 [cited by applicant]
WO WO2013026004A2 · 2013 [cited by applicant]
WO 2014165524A2 · 2014 [cited by applicant]
WO WO2015195835A2 · 2015 [cited by applicant]
WO 2016092419A1 · 2016 [cited by applicant]
WO WO2018064478A1 · 2018 [cited by applicant]
Ganesh et al., TGF-b Inhibition and Immunotherapy: Checkmate, Immunity, 48:626-628, Apr. 17, 2018. [cited by examiner]
Tsuji et al., Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function, J. Virol. 96(11), doi.org/10.1128/jvi.00071-22, 18 page, Ju… [cited by examiner]
Lan et al., Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β, Sci. Transl. Med. 10, eaan5488, 15 pages, Jan. 17, 2018. [cited by examiner]
Duan et al., Impact of PD-L1, transforming growth factor-B expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors, Thoracic Cancer 9 (2018) 1341-1353. [cited by examiner]
Ravi et al., Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy, Nat. Commun. 9:417, Feb. 21, 2018. [cited by examiner]
Herold et al., Determinants of the assembly and function of antibody variable domains, Scientific Reports, 7:12276, DOI:10.1038/s41598-017-12519-9, Sep. 2017. [cited by examiner]
Kranz et al. , Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies, Proc. Natl. Acad. Sci., USA, 78(9):5807-5811, 1981. [cited by examiner]
Sela-Culang et al., The structural basis of antibody-antigen recognition, Front. Immunol. 4:302, 13 pages, Oct. 2013. [cited by examiner]
Wu et al., Integrins as receptor targets for neurological disorders, Pharmacol. Therap. 134:68-81, 2012. [cited by examiner]
RS Nezlin, Biochemistry of Antibodies, (Plenum Press: New York) Translated by MC Vale, Ed. F. Karush, p. 160, 1970. [cited by examiner]
JP2021-512751 , “Office Action”, Nov. 28, 2023, 8 pages. [cited by applicant]
Abe M. et al., “An Assay for Transforming Growth Factor-B Using Cells Transfected With a Plasminogen Activator Inhibitor-1 Promoter-Luciferase Construct”, Analytical Biochemistry 216:276-284 (1994). [cited by applicant]
Akhurst R.J. et al., “Targeting TGF-B Signaling for Therapeutic Gain”, Cold Spring Harb Perspect Biol 9:a022301 (2017). [cited by applicant]
Akhurst R.J. et al., “Targeting the TGFB Signalling Pathway in Disease”, Nature Reviews Drug Discovery 11:790-811 (Oct. 2012). [cited by applicant]
Alegre M-L et al., “Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a “Humanzed” OKT3 Monoclonal Antibody”, The Journal of Immunology 148(11):3461-3468 (Jun. 1, 1992). [cited by applicant]
Annes J.P. et al., “Making Sense of Latent TGFB Activation”, Journal of Cell Science 116(2):217-224 (2003). [cited by applicant]
Arnold T.D. et al., “Defective Retinal Vascular Endothelial Cell Development as a Consequence of Impaired Integrin aVB8-Mediated Activation of Transforming Growth Factor-B”, The Journal of Neuroscience 32(4):1197-1206 (… [cited by applicant]
Ascierto P.A. et al., “Perspectives in Immunotherapy: Meeting Report from the “Immunotherapy Bridge”, Napoli, Nov. 30, 2016”, Journal of Translational Medicine 15:205, 21 pages, (2017). [cited by applicant]
Betts A. et al., “Linear Pharmacokinetic Parameters for Monoclonal Antibodies are Similar Within a Species and Across Different Pharmacological Targets: A Comparison Between Human, Cynomolgus Monkey and hFcRn Tg32 Trans… [cited by applicant]
Chen C. et al., “Enhancement and Destruction of Antibody Function by Somatic Mutation: Unequal Occurrence is Controlled by V Gene Combinatorial Associations”, EMBO J. 14(12):2784-2794 (1995). [cited by applicant]
Dodagatta-Marri et al., “a-PD-1 Therapy Elevates Treg/Th Balance and Increases Tumor Cell pSmad3 that are Both Targeted by a-TGFB Antibody to Promote Durable Rejection and Immunity in Squamous Cell Carcinomas”, Journal … [cited by applicant]
Edwards J.P. et al., “Release of Active TGF-B1 from the Latent TGF-B1/GARP Complex on T Regulatory Cells is Mediated by Integrin B8”, The Journal of Immunology 193:2843-2849 (2014). [cited by applicant]
Fenton TM et al., “Inflammatory Cues Enhance TGFB Activation by Distinct Subsets of Human Intestinal Dendritic Cells via Integrin avB8”, Nature 10(3):624-634 (May 2017). [cited by applicant]
Flavell R.A. et al., “The Polarization of Immune Cells in the Tumour Environment by TGFB”, Nature Reviews—Immunology 10:554-567 (Aug. 2010). [cited by applicant]
Franklin R.A. et al., “The Cellular and Molecular Origin of Tumor-Associated Macrophages”, Science 344 (6186):921-925 (May 23, 2014). [cited by applicant]
Gorelik L. et al., “Immune-Mediated Eradication of Tumors Through the Blockade of Transforming Growth Factor-B Signaling in T Cells”, Nature Medicine 7(10):1118-1122 (Oct. 2001). [cited by applicant]
Henderson N C et al., “Targeting of aV Integrin Identifies a Core Molecular Pathway that Regulates Fibrosis in Several Organs”, Nature Medicine 19(12):1617-1624 (Dec. 2013). [cited by applicant]
Herold K.C. et al., “Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus”, The New England Journal of Medicine 346(22):1692-1698 (May 30, 2002). [cited by applicant]
Hezareh M. et al., “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody Against Human Immunodeficiency Virus Type 1”, Journal of Virology 75(24):12161-12168 (Dec. 2001). [cited by applicant]
Huang X. et al., “The Integrin avB6 is Critical for Keratinocyte Migration on Both its Known Ligand, Fibronectin, and on Vitronectin”, Journal of Cell Science 111:2189-2195 (1998). [cited by applicant]
Kang S.W. et al., “Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand”, Cancer Research 77(21):5989-6000 (Sep. 2017). [cited by applicant]
Kueng W. et al., “Quantification of Cells Cultured on 96-Well Plates”, Analytical Biochemistry 182:16-19 (1989). [cited by applicant]
Ladner R C, “Mapping the Epitopes of Antibodies”, Biotechnol Genet Eng Rev 24:1-30 (2007). [cited by applicant]
Amminmaki U. et al., “Crystal Structure of a Recombinant Anti-Estradiol Fab Fragment in Complex With 17Beta-Estradiol”, J Biol Chem 276:36687-36694 (2001). [cited by applicant]
Liu C. et al., “Randomised, Double Blind, Placebo Controlled Study of Interferon B-1a in Relapsing-Remitting Multiple Sclerosis Analysed by Area Under Disability/Time Curves”, J Neurol Neurosurg Psychiatry 67:451-456 (1… [cited by applicant]
MacCallum R M et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography”, J Mol Biol. 262(5):732-745 (Oct. 1996). [cited by applicant]
Mariathasan S. et al., “TGFB Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells”, Nature 554:544-548 and extended data (Feb. 22, 2018). [cited by applicant]
Melton A.C. et al., “Expression of avB8 Integrin on Dendritic Cells Regulates Th17 Cell Development and Experimental Autoimmune Encephalomyelitis in Mice”, The Journal of Clinical Investigation 120(12):4436-4444 (Dec. 2… [cited by applicant]
Movahedi K. et al., “Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes”, Cancer Research 70(14):5728-5739 (2010). [cited by applicant]
Mu D. et al., “The Integrin avB8 Mediates Epithelial Homeostasis Through MT1-MMP-Dependent Activation of TGF-B1”, The Journal of Cell Biology 157(3):493-507 (Apr. 29, 2002). [cited by applicant]
Munger J.S. et al., “The Integrin avB6 Binds and Activates Latent TGFB1: A Mechanism for Regulating Pulmonary Inflammation and Fibrosis”, Cell 96:319-328 (Feb. 5, 1999). [cited by applicant]
Muyldermans S., “Nanobodies: Natural Single-Domain Antibodies”, Annu Rev Biochem. 82:775-797 (2013). [cited by applicant]
Nishimura H. et al., “Immunological Studies on PD-1-Deficient Mice: Implication of PD-1 as a Negative Regular for B Cell Responses”, International Immunology 10(10):1563-1572 (1998). [cited by applicant]
Noy R. et al., “Tumor-Associated Macrophages: From Mechanisms to Therapy”, Immunity 41:49-61 (Jul. 17, 2014). [cited by applicant]
Ostuni R. et al., “Macrophages and Cancer: From Mechanisms to Therapeutic Implications”, Trends in Immunology 36(4):229-239 (Apr. 2015). [cited by applicant]
Portielje J.E.A. et al., “IL-12: A Promising Adjuvant for Cancer Vaccination”, Cancer Immunol Immunother 52:133-144 (2003). [cited by applicant]
Proctor J.M. et al., “Vascular Development of the Brain Requires B8 Integrin Expression in the Neuroepithelium”, The Journal of Neuroscience 25(43):9940-9948 (Oct. 26, 2005). [cited by applicant]
Rock J.R. et al., “Multiple Stromal Populations Contribute to Pulmonary Fibrosis Without Evidence for Epithelial to Mesenchymal Transition”, PNAS 108(52):E1475-E1483 (Dec. 27, 2011). [cited by applicant]
Su G. et al., “Absence of Integrin avB3 Enhances Vascular Leak in Mice by Inhibiting Endothelial Cortical Actin Formation”, Am J Respir Crit Care Med 185(1):58-66 (Jan. 1, 2012). [cited by applicant]
Su G. et al., “Integrin avB5 Regulates Lung Vascular Permeability and Pulmonary Endothelial Barrier Function”, American Journal of Respiratory Cell and Molecular Biology 36:377-386 (2007). [cited by applicant]
Tauriello D.V.F. et al., “TGFB Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis”, Nature 554:538-543 (Feb. 22, 2018). [cited by applicant]
Terabe M. et al., “Blockade of Only TGF-B 1 and 2 is Sufficient to Enhance the Efficacy of Vaccine and PD-1 Checkpoint Blockade Immunotherapy”, Oncoimmunology 6(5):e1308616 (2017). [cited by applicant]
Thomas D.A. et al., “TGF-B Directly Targets Cytotoxic T Cell Functions During Tumor Evasion of Immune Surveillance”, Cancer Cell 8:369-380 (Nov. 2005). [cited by applicant]
Travis M.A et al., “Loss of Integrin avB8 Dendritic Cells Causes Autoimmunity and Colitis in Mice”, Nature 149:361-365 (Sep. 20, 2007). [cited by applicant]
Vanpouille-Box C. et al., “TGFB is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity”, Cancer Research 75(11):2232-2242 (Jun. 1, 2015). [cited by applicant]
Wei S.C. et al., “Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade”, Cell 170:1120-1133 (Sep. 7, 2017). [cited by applicant]
Wu T-C et al., “Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-Cell Differentiation and Breast Cancer Rejection”, Cancer Immunology Research 2(5):487-500 (2014). [cited by applicant]
Yang J.C. et al., “A Randomized Trial of Bevacizumab, and Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer”, The New England Journal of Medicine 349(5):427-434 (Jul. 31, 2003). [cited by applicant]
Young K.H. et al., “Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy”, PLoS One 11(6):e0157164 (2016). [cited by applicant]
Dahmani et al., TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. Cancers (Basel). Jun. 11, 2018;10(6):194. doi: 10.3390/cancers10060194, (21 pages). [cited by applicant]
Fenton et al., Inflammatory cues enhance TGFβ activation by distinct subsets of human intestinal dendritic cells via integrin αvβ8. Mucosal Immunol. May 2017;10(3):624-634. doi: 10.1038/mi.2016.94. Epub Oct. 26, 2016. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/049748, mailed Dec. 16, 2019. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/049748, mailed Mar. 18, 2021. [cited by applicant]
Hargadon et al., Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. Sep. 2018;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub Jul. 2, 2018. [cited by applicant]
Leger et al., Humanization of Antibodies. Chapter 1 in: Antibody Drug Discovery. Imperial College Press, Eds. 2012; 4: 1-23. https://doi.org/10.1142/9781848166295_0001. [cited by applicant]
Mariuzza et al., The Structural Basis of Antigen-Antibody Recognition. Annu Rev Biophys Biophys Chem. 1987;16:139-59. doi: 10.1146/annurev.bb.16.060187.001035. [cited by applicant]
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83. doi: 10.1073/pnas.79.6.1979. [cited by applicant]
Safdari et al., Antibody humanization methods—a review and update. Biotechnol Genet Eng Rev. 2013;29:175-86. doi: 10.1080/02648725.2013.801235. Epub Aug. 2, 2013. [cited by applicant]
Stockis et al., Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8. Proc Natl Acad Sci U S A. Nov. 21, 2017;114(47):E10161-E10168. doi: 10.1073/pnas.1710680114. Epub Nov. 6, 2017. [cited by applicant]
Wang et al., IgG Fc engineering to modulate antibody effector functions. Protein Cell. Jan. 2018;9(1):63-73. doi: 10.1007/s13238-017-0473-8. Epub Oct. 6, 2017. [cited by applicant]
Dirks, Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer. J Clin Oncol. Jun. 10, 2008;26(17):2916-24. doi: 10.1200/JCO.2008.17.6792. [cited by applicant]
LÓPEZ-LÁZARO, The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking metastasis. Oncoscience. May 1, 2015;2(5):467-75. doi: 10.18632/oncoscience.159. eCollection 2015. [cited by applicant]
Tran et al., Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci. Apr. 2010;17(4):417-21. doi: 10.1016/j.jocn.2009.09.004. Epub Feb. 18, 2010. [cited by applicant]
Singer, et al., Genes and Genomes—A changing perspective. University Science Books, Eds. 1991, p. 63. [cited by applicant]
CN2019980057769.8, “Office Action”, Feb. 23, 2024, 6 pages. [cited by applicant]